It is not FDA approved
Retatrutide remains experimental and has not yet been approved by the U.S Food and Drug Administration
As of now, retatrutide is primarily available through clinical trials or specialized research programs
Retatrutide 5.0 (4 reviews) Retatrutide (LY3437943) is a synthetic triple agonist engaging the GIP, GLP-1 and glucagon receptors, supplied as a lyophilised powder for research and laboratory use only
Dietary Reference Intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids
Statements estimating treatment duration and the number of treatments required are based on the typical experience of our patients, however, individual experiences may vary